London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Many thanks for all the replies.
There are truly some amazing people working in this field, often for little financial reward.
Let’s hope Scancell is the spark that makes the giant breakthrough.
Matt,
It's a long time ago now but worth remembering that the one commercial success Scancell have had was in glycan mAbs when they sold their pipeline to Peptech for £4.85m. Hopefully history will repeat itself , time will tell.
You also asked about what the Nottingham Trent study means for Scancell and the honest answer is probably not a great deal at the moment. It's very early stage and may or may not progress further. My own take is simply that it's an endorsement of the ImmunoBody platform from Lindy Durrant's peers and therefore positive news.
IMO of course
Yes
These are scientists we are talking about, not business men.
NU recognised that, without Lindy, glycans mabs would almost certainly not exist.
Their decision to allow Scancell to progress the science has already been shown to be correct so far.
The hope now is that all 3 companies will have a fight over who will now attempt to carry the science through to fruition.
CH the auctioneer watching the bid rise is the best possible outcome.
Good question Matt, and I have often felt some of the criticism afforded to certain members of the BOD is at times hysterical, not factual, and in most cases especially over on ADVFN not relevant to the hear and now.
There was a good article in Fierce Biotech today written by Brad Loncar (a name we have seen on Scancell Twitter, discussingthe top IPOs from 2018/2019 and in all cases the companies are in at least Phase 1 trials, with high expectancy from any data they have recorded. I don"t think many here have any illusions as to the imposrtance of us too being in trials, collecting data which will determine our potential worth. We are nearing that stage across three platforms. The current SP reflects our position and there is still uch we don"t know as to what has caused delays, but stillsome will blame JC or CH in sweeping statements to proportion blame and fulfil in many casesa clear agenda in seeing Scancel fail
As I have said the current SP reflects where we are now and I feel we should spend more time focusing on the here and now, risk/reward at current levels, I do not see the purpose of trying to still proportion blame to another company at a different time with high expectations and a share prie suitably inflated. So a simple answer why have faith in Scancell"" perhaps they kmow better where we are at, the capabilities of the company as it has grown and a confidence even in Vilpes/Martin Diggle to secure commercial deals at this stage. I personally don"t feel we have been in a better position before as we are now and NTU know better than our so called self declared experts over on ADVFN how we are set up for the here and now at the prices we have fallen to by delays in the last few years. So why would they have faith...............well it exists because they see more than we do, and are in abetter position to make judgements without any agendas that exist. ATB
Yes it would be interesting to know what happened or did not happen there.... are they now 2 of the collaborators for instance... we will probably never find out but I think getting deals on MaBs might just be something JC and CH are efficient at as is their area from their previous experience
I seem to remember that whilst Lindy was developing the glycans mabs at NU there was already interest from 2 companies.
https://vimeo.com/155954442
They also could not afford to protect the IP which scancell is doing... basically, they are all family anyways the young lady who was most involved in their development is now also a full-time scancell employee... strengthening of scancell team science
I see what you mean crumbs.
Well I think the answer is that Lindy developed the glycans mabs with her NU hat on.
NU obviously considered she was best placed to carry it further.
Having humanised the mabs Lindy realised they were going to fail with lower than expected avidity. They had lost their killing ability.
Then Lindy developed Avidimab with her Scancell hat on and the situation totally changed.
NU had faith in their star player.
Ray, I think he is talking about Glycans/Avidimab....obviously oblivious to them already attracting 3 collaborators and expected 'transaction later in the year'
Their work is based on Scancell's proprietary platform Immunobody.
Many thanks for all the replies.
Again, with a neutral view to my question, why would they have any faith in Scancell commercialising this since we haven’t commercialised anything at all.
I ask this as a LTH.
Why not go the North American or Chinese route?
Limiting themselves to an AIM company is surely not the best strategy? Why not offer their idea up to the highest bidder?
https://www.ntu.ac.uk/search?query=scancell
The John van Geest Cancer Research Centre is just across the River Trent from the building where Lindy works.
Probably both buildings are in the River Trent at present
Would appear with the glycans agreement NU have a lot of confidence in Scancell to commercialise it. Certainly more confidence than some LTHs hold with our existing platforms.
Totally agree C7.
She uses her dual role to Scancell's benefit IMO.
It's such a great relationship she has with NU. The gylcans agreement is a great example of this.
I'm speculating that she has a similar relationship with NTU.
Its a win-win for both parties.
There have been more than a few occasions where I wondered how much Lindys dual role affected the time she could spend on Scancell, seems clearer now the benefits to Scancell . IMO
I should add without scancell having to pay for them win win
Potential trials using ImmunoBody in 2 new targets
NTU posts today.
I’m not being positive or negative but what does any of this do for SCLP.
Anything or nothing?